American biopharmaceutical giant Amgen is set to expand its Dún Laoghaire facility with the creation of 728 new positions over the next six years, bringing total employment at the south Dublin site to 2,544 staff members by 2030. The substantial workforce expansion underscores Ireland’s continued attractiveness as a strategic location for life sciences manufacturing and research operations.
The planned recruitment drive represents a 40 percent increase from current staffing levels at the coastal Dublin facility, which serves as a critical manufacturing hub within Amgen’s global operations network. This employment growth aligns with broader trends in Ireland’s pharmaceutical and biotechnology sectors, which have consistently demonstrated resilience and expansion despite global economic uncertainties.
Amgen’s Dún Laoghaire operation plays a vital role in the company’s international production capabilities, focusing on advanced biologic drug manufacturing. The facility produces treatments for serious illnesses including cancer, kidney disease, and inflammatory conditions, contributing significantly to both Ireland’s pharmaceutical exports and the company’s worldwide supply chain. The site has established itself as a centre of excellence for biologics manufacturing since operations commenced.
Ireland’s biopharmaceutical industry continues to attract substantial foreign direct investment, supported by a skilled workforce, competitive corporate environment, and strong regulatory framework. IDA Ireland has positioned the life sciences sector as a cornerstone of the country’s industrial strategy, with multinational pharmaceutical companies accounting for a significant portion of Ireland’s total exports and contributing billions annually to the national economy.
The jobs announcement comes at a time when Ireland’s pharmaceutical manufacturing sector employs over 40,000 people directly, with the industry representing one of the highest value-adding segments of the Irish economy. Companies operating in this space benefit from Ireland’s membership in the European Union, providing streamlined access to the single market of approximately 450 million consumers, alongside established logistics infrastructure and a highly educated talent pool.
Amgen’s expansion decision reflects confidence in Ireland’s continued competitiveness within the global biopharmaceutical landscape. The company joins other major players in the sector that have recently announced significant Irish investments, reinforcing the country’s reputation as a preferred European location for high-value pharmaceutical manufacturing and research activities.
The recruitment timeline extending to 2030 suggests a phased approach to workforce development, allowing the company to align staffing increases with capacity expansions and production requirements. This gradual growth pattern enables effective integration of new employees while maintaining operational excellence and regulatory compliance standards essential to pharmaceutical manufacturing.
For the Dún Laoghaire area and wider Dublin region, the employment boost provides a significant economic stimulus, with highly skilled biopharmaceutical positions typically offering competitive salaries and benefits packages. The positions are expected to span multiple disciplines including manufacturing operations, quality assurance, engineering, supply chain management, and technical support roles.
Ireland’s pharmaceutical sector has demonstrated particular strength in biologics manufacturing, an area requiring sophisticated facilities and specialized expertise. Enterprise Ireland has supported the development of indigenous supply chain companies serving this sector, creating additional employment opportunities and strengthening Ireland’s overall life sciences ecosystem.
The announcement reinforces predictions that Ireland’s pharmaceutical industry will continue expanding through the remainder of the decade, driven by increasing global demand for biologic medicines and the sector’s ongoing innovation in treatment development. With multiple major pharmaceutical companies maintaining substantial Irish operations, the country has established itself as an indispensable component of global healthcare supply networks.
